Roche entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg, an investigational oral drug targeting blood cancers, in a deal valued at up to $2.3 billion, the companies said Monday.
Nurix will receive $700 million in cash upfront, with additional payments based on development, regulatory, and sales milestones
The total value could reach $2.3 billion. Roche will cover 60% of development costs, while Nurix will pay the remaining 40%. Within the U.S. market, the two companies will share any profits or losses on an even basis.
For sales elsewhere, Roche takes the commercial lead and compensates Nurix through royalties in the low- to high-teens percentage range, the company said. The deal is expected to close in the third quarter of 2026, according to RTTNews. Bexobrutideg works by recruiting the body’s own protein-destruction machinery to break down Bruton’s tyrosine kinase, or BTK, an enzyme whose signaling activity drives the growth and survival of certain blood cancer cells.